News Johnson & Johnson Borsa Italiana

Equities

4JNJ

US4781601046

End-of-day quote Borsa Italiana Other stock markets 23:00:00 19/06/2024 BST			5-day change	1st Jan Change
136 ^EUR	+0.38%		-1.98%	-3.29%

06-28	Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial	MT
06-28	J&J Unit's Rybrevant Combo Gets EU Approval	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Johnson & Johnson : CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients	06-28	PU
Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial	06-28	MT
J&J Unit's Rybrevant Combo Gets EU Approval	06-28	MT
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients	06-28	PR
Johnson & Johnson Announces Positive Results from the Nipocalimab Phase 3 Vivacity-MG3 Study	06-28	CI
Johnson & Johnson : CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients with unresectable or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations	06-28	PU
Johnson & Johnson's Balversa Gets EU Panel Recommendation for Urothelial Carcinoma	06-28	MT
Dealmakers optimistic on global M&A prospects despite sluggish growth	06-28	RE
Lawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in Purdue	06-27	BU
A New Wave Of ERISA Class Actions?: Some Employer/Fiduciary Implications Of Lewandowski V. Johnson & Johnson (Podcast)	06-27	AQ
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	06-27	RE
Johnson & Johnson Reaches 50 Million Children Through Sight For Kids Program	06-25	AQ
US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit	06-24	RE
J&J: 50M pupils helped through 'Sight for Kids' program	06-24	CF
Johnson & Johnson completes acquisition of Proteologix, Inc.	06-24	AQ
Sector Update: Health Care Stocks Edge Up in Afternoon Trading	06-21	MT
Johnson & Johnson: filing in Crohn's disease	06-21	CF
Johnson & Johnson: acquisition of Proteologix completed	06-21	CF
Johnson & Johnson Completes Acquisition of Proteologix	06-21	MT
Johnson & Johnson Completes Acquisition of Proteologix	06-21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 05:30 pm